Effects of raloxifene, hormone therapy, and soy isoflavone on serum high-sensitive C-reactive protein in postmenopausal women.
OBJECTIVE
To compare the effects of raloxifene, estradiol valerate plus dienogest, and soy isoflavones (genistein) on serum concentrations of high-sensitive C-reactive protein in healthy postmenopausal women.


METHODS
The 80 healthy postmenopausal women enrolled in the study were randomly allocated to receive 60 mg of raloxifene, 2 mg of estradiol valerate plus dienogest, 40 mg of genistein, or placebo (n=20 in each group). Blood samples were collected at the start of the study and at 3 and 6 months. Lipid profile was also determined.


RESULTS
Only the group receiving estradiol valerate plus dienogest showed an increase in serum levels of high-sensitive C-reactive protein compared with baseline values and values in the control and other groups. All 3 treatments resulted in an increase in high-density lipoprotein cholesterol levels and a decrease in total, low-density, and very-low-density lipoprotein cholesterol levels.


CONCLUSIONS
Estradiol valerate plus dienogest, but not raloxifene and genistein, increase serum high-sensitive C-reactive protein levels. All 3 treatments, however, have an estrogen-like effect on serum lipid profile.
Yildiz
M Fahrettin
MF
Department of Obstetrics and Gynecology, Firat University Medical School, Elazig, Turkey.
Kumru
Selahattin
S
Godekmerdan
Ahmet
A
Kutlu
Selim
S
D002097:C-Reactive Protein / Q000032:analysis*; D002784:Cholesterol / Q000097:blood; D004958:Estradiol / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000494:pharmacology; D015914:Estrogen Replacement Therapy / Q000379:methods*; D005260:Female; D006801:Humans; D007529:Isoflavones / Q000008:administration & dosage / Q000494:pharmacology*; D008074:Lipoproteins / Q000097:blood; D008875:Middle Aged; D009277:Nandrolone / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000494:pharmacology; D017698:Postmenopause / Q000097:blood*; D011446:Prospective Studies; D020849:Raloxifene Hydrochloride / Q000008:administration & dosage / Q000494:pharmacology*; D013025:Glycine max / Q000737:chemistry; D016896:Treatment Outcome
D007529:Isoflavones; D008074:Lipoproteins; C023635:dienogest; D020849:Raloxifene Hydrochloride; D004958:Estradiol; D009277:Nandrolone; D002097:C-Reactive Protein; D002784:Cholesterol